Can a psoriasis drug stop transplant rejection?
NCT ID NCT04572815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether the drug ustekinumab (Stelara) can prevent acute graft-versus-host disease (GVHD) in 116 adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. Ustekinumab aims to calm this immune response. Participants receive either the drug or a placebo, and researchers track how many develop GVHD over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ustekinumab (Stelara)
What this could lead to
If it works, this could offer a new way to prevent graft-versus-host disease, a serious complication after stem cell transplants.
What could go wrong
This is an early phase II trial with only 116 participants, so results may not apply to everyone. The drug may not reduce GVHD risk and could have side effects like infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center,
Duarte, California, 91010, United States
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States